Skip to content
As Congress, the U.S. Federal Trade Commission (FTC), and industry are taking a closer look at pharmacy benefit managers (PBMs), a new report highlights […]
New studies highlight PBMs’ profit sources, customer dissatisfaction Read More »
On September 22, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted 11-1 to recommend one dose of
More good news for pediatric RSV immunizations Read More »
“The biotech sisterhood is the antidote to the pharma bros,” said Angie You, Ph.D., Chief Executive Officer at Architect Therapeutics, during a lively conversation
Meet the biotech sisterhood—women supporting women in the pharma sector Read More »
With the beginning of respiratory syncytial virus (RSV) season, there is no better time to bring awareness to the efforts going into therapeutic research
Afrobodies’ custom antibodies make use of a unique animal: the alpaca Read More »
Drug price controls in the Inflation Reduction Act (IRA) harm the development of new drugs, according to Sept. 20 testimony in Congress from John
BIO Vice Chair John F. Crowley to Congress: IRA reduces access to innovative drugs Read More »
We need to make progress against the next pandemic, Phyllis Arthur, Senior Vice President of Infectious Diseases & Emerging Science Policy at the Biotechnology
Plan now for next pandemic, BIO’s Phyllis Arthur tells UN preparedness panel Read More »
On September 20, the House Energy & Commerce Oversight and Investigations Subcommittee will explore how the drug price controls in the Inflation Reduction Act
BIO Vice Chair John F. Crowley to testify on Inflation Reduction Act price controls Read More »
Between the buzzing and the painful stings, one might argue that bees can be annoying. But to put it simply: if bees go extinct,
Can biotech save the bees? Read More »
Lawmakers introduced the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act) on September 18, a bill the Biotechnology Innovation Organization (BIO) said
ORPHAN Cures Act introduced to boost new rare disease drug development Read More »
Within the challenging field of protein misfolding research, there is a company with a unique and competitive edge that is turning heads and making
BIO’s Emerging Start-Up Stadium winner: Paradox Immunotherapeutics Read More »
